Showing 4061-4070 of 5911 results for "".
- Carl Zeiss Meditec to Acquire Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-to-acquire-dutch-ophthalmic-research-center-dorc/2482014/In a move to expand its position in the vitreo-retinal surgery segment and strengthen its position in the ophthalmic medical device category globally, Carl Zeiss Meditec announced it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Cente
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Ashley Magargee Named CEO of Genentechhttps://modernod.com/news/genentech-names-ashley-magargee-as-ceo/2482008/Ashley Magargee has been appointed Chief Executive Officer (CEO) of Genentech, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Ms. Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will repo
- Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GAhttps://modernod.com/news/ocugen-announces-first-patient-dosed-in-phase-12-trial-of-ocu410-modifier-gene-therapy-for-ga/2482006/Ocugen announced that the first patient has been dosed in the ArMaDa phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (AMD). This phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic at
- Belkin Vision Announces FDA Clearance for the Eagle for Selective Laser Trabeculoplastyhttps://modernod.com/news/belkin-vision-announces-fda-clearance-for-the-eagle-device/2482005/Belkin Vision has received FDA 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser intended for use in performing selective laser trabeculoplasty (SLT). Belkin describes the Eagle as the first and only contactless l
- Optometry Giving Sight Earns Four-Star Rating From Charity Navigatorhttps://modernod.com/news/optometry-giving-sight-earns-four-star-rating-from-charity-navigator/2482001/Optometry Giving Sight (OGS) has announced that its strong financial health and ongoing accountability and transparency have earned a Four-Star rating from Charity Navigator. This rating designates Optometry Giving Sight as an official “Give with Confidence” charity, indicating t
- Zeiss Announces New Biometry Mastery Courses in 2024https://modernod.com/news/zeiss-announces-new-biometry-mastery-courses-in-2024/2482000/Carl Zeiss Meditec is launching the Biometry Mastery Course, a program designed to enhance the skills and expertise of ophthalmic professionals. The Zeiss Biometry Mastery Course is a training initiative aimed at equipping nurses and technicians with advanced knowledge and practica
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- iHealthScreen Announces MHRA Certification and Registration for iPredict Automated AI Systemhttps://modernod.com/news/ihealthscreen-announces-mhra-certification-and-registration-for-ipredict-automated-ai-system/2481997/iHealthScreen has received UK Medicines and Healthcare Products Regulatory Agency (MHRA) certification and registration for its iPredict AI Eye Screening System, which is used for the early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma. <
- Horus Pharma Strengthens Its International Expansionhttps://modernod.com/news/horus-pharma-strengthens-its-international-expansion/2481996/Horus Pharma, a France-based provider of preservative-free ophthalmology products, announced it is strengthening its international presence with eight distribution agreements covering Romania, Portugal, Croatia, Turkey, Algeria, Qatar, Ireland, and Bosnia. The deals take